The U.S. Food and Drug Administration (FDA) has set Feb. 1, 2025, as a goal date for deciding whether to approve SPN-830, an apomorphine infusion pump, for the continuous treatment of off episodes in Parkinson’s disease. That’s according to a financial update from the device’s developer,…
Irlab Therapeutics’ oral therapy IRL757 was safe and well tolerated in healthy volunteers in the first part of a Phase 1 study testing the therapy, a potential treatment for apathy in patients with Parkinson’s disease and other neurological conditions. “This bodes well for the further clinical development of a…
Aspen Neuroscience has opened a manufacturing facility for ANPD001, its investigational stem cell therapy for Parkinson’s disease being used in an ongoing Phase 1/2a clinical trial. The 22,000-square-foot facility is an expansion of the company’s headquarters near San Diego, and is reported to include three manufacturing suites certified…
A neural platform based on graphene, a strong but extremely thin carbon sheet that Inbrain Neuroelectronics is developing for a surgical treatment of Parkinson’s disease, was used for a first time on a patient undergoing brain tumor surgery. The platform’s graphene-based brain-computer interface (BCI) technology demonstrated an ability…
Reasonable safety is being seen in a first group of Parkinson’s disease patients who finished dosing in a Phase 1/2a clinical trial of ANPD001, Aspen Neurosciences’ investigational stem cell therapy aiming to replace the nerve cells lost to the disease. The three treated adults were given two…
A compound called IU1 may improve the body’s ability to maintain healthy proteins by boosting two critical processes that play a role in removing damaged proteins from cells, a study shows. The findings could have implications for age-related conditions like Parkinson’s disease. The study, “Pharmacological inhibition of…
A mutation in the RAB32 gene, which has been previously associated with Parkinson’s disease, was found in a significant number of individuals participating in an international study. Specifically, researchers found this mutation more than 100 times more prevalent in Parkinson’s patients than in the general population. These data came…
A small compound that acts as a molecular glue can activate a protein that’s often mutated in people with early-onset Parkinson’s disease, a study finds. By activating parkin, the compound enables the protein to perform its function of removing damaged mitochondria, thereby helping maintain the health of brain cells.
A National Institutes of Health (NIH) grant will fund the creation of a brain-on-a-chip technology, a microengineered device containing nerve cells and blood vessels to help scientists more fully understand how neurodegenerative diseases like Parkinson’s and Lewy body dementia affect their ability to function. Jungwook Paek, PhD,…
Get regular updates to your inbox.